Practical Aspects of Dissolution Instrument Qualification a European Perspective
|
|
- Anis Marybeth Jennings
- 6 years ago
- Views:
Transcription
1 dx.doi.org/ /dt180211p11 Practical Aspects of Dissolution Instrument Qualification a European Perspective JKraemer@phast.com Johannes Kraemer* and Rolf Schwan PHAST, Kardinal-Wendel-Str. 16, Homburg, Germany INTRODUCTION Dissolution testing is an important tool to characterize the in vitro performance of dosage forms. It is not an absolute method; strictly speaking, equipment cannot be calibrated. Instead, from the perspective of a quality control (QC) laboratory, reliable instrument qualification is one of the most important requirements of cgmp. While harmonization efforts for qualification strategies of standard laboratory equipment lead, in most cases, to clear and undisputed approaches, the standardization of dissolution apparatus qualification procedures is still ongoing. The most common USP Apparatus 1 and 2 are used in pharmaceutical laboratories worldwide to perform quality control analyses either during the manufacturing process (PAT) or as part of release testing. Moreover, they are used to monitor formulations throughout pharmaceutical development. Drug candidate selection for clinical studies is based on differences attributed to manufacturing variables during a Quality by Design (QbD) oriented development, whereas the release of marketed products relies on the dissolution similarity of manufactured batches in comparison to the models described in the dossiers for registration. This underlines the need for reliable dissolution data. A study of the relevant rules and procedures reveals that dissolution apparatus qualification consists of two parts: a mechanical qualification and a performance test with a reference standard. In detail, the leading documents concerning dissolution apparatus qualification [e.g., United States Pharmacopoeia (USP) and the European Pharmacopoeia (EP) on the one hand and ASTM E and FDA Guidance for Industry (1) on the other hand] do not advise identical procedures and specifications. Proposals were made for procedures to match the so-called chemical and mechanical qualification (2) but are still leaving some uncertainty at QC testing labs. In the past, harmonization efforts like ICH Q4B took effect and harmonized the respective chapters of the USP and the EP. One remaining difference is the EP nonmandatory recommendation of the use of a reference product that is sensitive to hydrodynamic conditions for performance testing, while USP requires the use of its reference tablet. *Corresponding author. This article describes the authors strategy and observations when performing mechanical and chemical qualification of dissolution Apparatus 1 und 2 in a typical QC laboratory that has to follow both United States and European requirements. SOURCES OF VARIABILITY FOR DISSOLUTION TESTING Proper QC testing targets the accurate and precise characterization of product in vitro performance. The principal goal of a QC testing laboratory is therefore to minimize the artifacts that may potentially increase both patient and pharmaceutical manufacturer risk. General sources of variability may arise from the testing procedure, the instrument, and the analyst in addition to the inherent properties of the drug product. Relevant sources of variability are listed in Table 1. Modern dissolution testing mostly uses automated systems consisting of the dissolution apparatus, a sampling and processing unit, and an instrument for quantification. For each testing run, the operational variables are adjusted because they may influence the results. These are the stirring rate, the temperature, the medium volume, and the sampling schedule. They are not part of the qualification process. These factors are individually programmed and are thus subject to random errors. In addition to the factors mentioned above, permanent and systematic errors leading to highly biased data may be generated by the apparatus itself. Inherent instrument-related sources of variation that may influence the dissolution results (e.g., by altering fluid dynamics) are listed in Table 2. The primary goal of routine qualification and requalification is to prove that each individual parameter is within the specifications set by the pharmacopeias and, importantly, that the sum of all tolerable deviations has no relevant impact on the results. ENHANCED MECHANICAL QUALIFICATION IQ AND OQ CHECKPOINTS AND LIMITATIONS We developed our standard operating procedure (SOP) for the qualification of dissolution apparatus used for QC testing based on a risk analysis. The concept of this SOP is an enhanced mechanical qualification in line with pharmacopeial requirements. This SOP contains specifications that, in some cases, may be more stringent than USP or EP recommendations. The SOP only allows performance 11 diss indd 11
2 12 Table 1. Sources of Variability in Dissolution Testing Lab environment Medium preparation Dissolution testing apparatus Sampling, transfer, processing (filtration, dilution, storage) of solutions Analytical instruments and the method used for quantification Testing procedure Analyst verification testing (PVT) after successful mechanical qualification. Selected IQ and OQ checkpoints as well as the specifications of our internal SOP are given in Table 3. However, not all potential factors of influence, such as the inner surface of the vessel, vibration, or their combination, may be covered by a qualification strategy limited solely to mechanical qualification. The design of most modern dissolution testers incorporates precisely controlled physical parameters, test conditions, and alignment to ensure that the release of drug from a dosage form will be determined consistently from one tester to another and from one laboratory to another. However, apparatus performance may contribute to interlaboratory variability as demonstrated from the results generated in laboratories that participated in global collaborative trials (3). In addition to these arguments for a staggered use of USP Prednisone Tablets RS, the following example shows that isolated physical-parameter checking is not a substitute for the performance verification test of the instrument run under operational conditions. Because of design features, physical checkpoints may not be accessible during operation. The results depicted in Figure 1 show the malfunction of an autocentering lid after mechanical qualification successfully passed. Table 2. Instrument-Related Sources of Variability for Dissolution Results Levelness of plate and lid Vessel dimensions, asymmetry and surface irregularities Instrument vibrations Verticality of vessel and/or stirrer shaft Rotation speed variations Wobble, height and centering of stirring elements Paddle or basket dimensions including irregularities Sampling probes and positioning Table 3. IQ and OQ Checkpoints Taken from PHAST SOP for Mechanical Qualification Part Checkpoint Specification Dissolution apparatus Installation location Vibration Work environment Installation on a leveled and stable workbench No additional sources of vibration in the work environment Constant conditions, no direct ventilation Vessels Dimensions Conform to USP <711> / Ph. Eur. all vessels from the same vendor Centering Assignment Maximal deviation from vertical axis of the shaft 1.0 mm Vessels are clearly assigned to test centers Shafts Dimensions Conform to USP <711> / Ph. Eur. Wobble Assignment Shafts are clearly assigned to test centers Paddles Dimensions Conform to USP <711> / Ph. Eur. Wobble Height Distance to the bottom of the vessel 25 mm ± 2 mm Baskets Dimensions Conform to USP <711> / Ph. Eur. Mesh size Wobble at the lower rim Height Test centers Assignment Clearly assigned Thermostat Sampling unit Rotation Speed Temperature accuracy Temperature stability Positioning Distance to the bottom of the vessel 25 ± 2 mm 50 rpm ± 2 rpm (±4%) 100 rpm ± 4 rpm (± 4%) Adjustment to 37.0 ± 0.5 C, temperature check before and after a dissolution run Conform to USP <711> / Ph. Eur. SOURCES OF ERROR ON VERIFICATION TESTING WITH THE USP PREDNISONE TABLETS RS The use of a qualified tablet formulation is well accepted in a laboratory designed for routine tablet testing. However, the USP Prednisone Tablets RS are not optimized for fast and complete dissolution like a conventional oral immediate-release drug product. Instead, slow dissolution within a reasonable time is needed for a qualification product to detect instrument diss indd 12
3 Figure 1. PVT of USP Apparatus 2 with an autocentering malfunction at vessel 1. impact on the rate. A typical slow-release product would not be suitable because one of the goals of slow-release products is robustness against physiological and mechanical impact. This may not match the need of sensitivity to mechanical deficiencies. Moreover, this product must be qualified by collaborative trials of laboratories that need clear qualification themselves. Only after independent qualification is the product considered suitable. From the European perspective, the USP Prednisone Tablets RS may be such a product. They are used in our laboratory following successful mechanical qualification to prove the performance of the apparatus. Examples are taken from real-life performance verification tests according to USP (USP Prednisone Tablets RS, 500 ml water, 50 rpm, 30-min sampling). Some remarkable observations were made in the course of numerous qualification runs. The manual and staggered sample insertion process is mentioned as one example of a constructional deficiency in some instruments. USP <711> requires application of the tablet before the start of stirring. Autosampling devices are disconnected for qualification of the bath. This requires a staggered start to leave time for sampling. With a particular apparatus, all spindles are driven by a belt that is connected to the central motor via a clutch. This does not allow a properly staggered start. After application of the first USP Prednisone Tablets RS, a staggered immersion of rotating spindles is required. While manually lowering the individual spindle to the final position previously adjusted to 25 mm, rotation may be hindered. The clutch compensates for the friction, which has an effect on all spindles. Thus, the rotation speed may be slightly higher for a limited time after release. The sum of all individual rotation-speed discontinuities is greatest for the first, and lowest for the last, USP Prednisone Tablets RS applied. The exposure time to the initially increased hydrodynamic Figure 2. PVT of USP Apparatus 2. Relation of initial clutch compensation after staggered insertion of connected spindles. The latest insertion has the lowest dissolution rate. Application sampling times corrected for delay. forces is related to the amount dissolved after 30 min. This relation is depicted in Figure 2. PVT FAILURE DUE TO PRECISE RESULTS AFTER HEIGHT MANIPULATION OF PADDLES During one root-cause analysis, we also investigated the impact of small deviations from the physical specifications. We used an apparatus with 12 positions. The first six paddles (1 6) were adjusted to exactly 25 mm from the center of the hemispherical bottom. The other positions (7 12) were adjusted to 24 mm, which is still in specification. The geometric mean (GM) of the first six vessels differed by 3% from the GM of vessels This Figure 3. PVT of USP Apparatus 2 showing sensitivity of PVT toward height adjustment. Distance for vessels 1 6 was 25 mm and for vessels 7 12, the distance was 24 mm. 13 diss indd 13
4 Figure 5. Deposits on basket wires. 14 Figure 4. PVT testing of USP Apparatus 1. (A) Floating USP Prednisone Tablets RS. (B) USP Prednisone Tablets RS sitting at the lower bottom mesh of the basket. demonstrates precision and sensitivity of the USP Prednisone Tablets RS to minor changes in hydrodynamic conditions. While the separate analyses of vessels 1 6 and 7 12 met the stringent first-stage criteria of the two-stage procedure, the entire data set did not meet the specifications for the one-stage procedure with twelve vessels. These findings, depicted in Figure 3, may lead to further harmonization of mechanical and PVT procedures. IMMERSION OF BASKETS The sample insertion process appears to be critical for Apparatus 1. Even after proper degassing, air may be entrapped in the basket depending on the lowering speed of the basket. Air bubbles may adhere to USP Prednisone Tablets RS as well as to particles after disintegration, causing floatation. Particles inside the basket are exposed to higher shear forces than particles settled on top or throughout the meshes into zones of lower hydrodynamic activity. Hence, floating particles and tablets are often the cause of higher dissolution results for the PVT. The effect of floating tablets is shown in Figure 4. Floating USP Prednisone Tablets RS dissolved with an RSD of 7.9%, whereas PVT sitting on the bottom mesh of the basket dissolved with an RSD of 2.5%. This meets the specification of 7.7% for lot P1I300 in the first stage of the two-stage-testing procedure. INSUFFICIENT BASKET CLEANING Other issues that have been identified through the PVT are basket deficiencies and basket meshes clogged by air bubbles even after proper degassing. The effect of insufficient cleaning is shown in Figure 5. Air bubbles adhered to an unclean wire surface when baskets were immersed. Mesh openings tended to be partly or completely clogged by bubbles. Particles were retained longer in an environment of higher hydrodynamic activity leading to high results. These observations were made after several out-of-calibration results were obtained, and resulted in a revised cleaning procedure for the baskets. WISH LIST FOR IMPROVED USP PREDNISONE TABLETS RS Although the practical experiences with the PVT lead to improved preconditions in dissolution testing, not all sources of failure could be eliminated. Due to stability effects of properly stored USP Prednisone Tablets RS, paddle apparatus qualification in the past failed reproducibly with results that were too low. The effect, which was known to the USP, led to a resetting of specifications. More stable USP Prednisone Tablets RS, preferably with a shelf-life specification, are desired in the future. diss indd 14 5/27/2011 1:54:43 PM
5 SUMMARY AND CONCLUSION An extensive qualification strategy for dissolution Apparatus 1 and 2 may combine meaningful mechanical qualification with the use of reliable standard tablets like the USP Prednisone Tablets RS. Instrument quality has largely improved over the last decades. Vessel quality and mounting provide room for further improvement as shown by Marc Liddell (4). The USP Prednisone Tablets RS may need to be improved as well. Reformulation with ongoing stability studies is desired. This may not be an easy task because sensitivity to the combination of factors, each individually not violating the specifications of mechanical qualification, would have to go in line with greatest robustness of use. Finally, both similarities and differences between the USP Prednisone Tablets RS and any pharmaceutical tablet product may need to be explained to users. REFERENCES 1. The Use of Mechanical Calibration of Dissolution Apparatus 1 and 2 Current Good Manufacturing Practice (CGMP); Guidance for Industry; U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), U.S. Government Printing Office: Washington, DC, January, Brown, C.; Buhse, L.; Friedel, H.; Keitel, S.; Kraemer, J.; Morris, M.; Stickelmeyer, M.; Yomota, C.; Shah, V. FIP Position Paper on Qualification of Paddle and Basket Dissolution Apparatus. Dissolution Technol. 2009, 16 (4), Deng, G.; Ashley, A. J.; Brown, W. E.; Eaton, J. W.; Hauck, W. W.; Kikwai, L. C.; Liddell, M. R.; Manning, R. G.; Munoz, J. M.; Nithyanandan, P.; Glasgow, M. J.; Stippler, E.; Wahab, S. Z.; Williams, R. L. The USP Performance Verification Test, Part I: UDP Lot P Prednisone Tablets Quality Attributes and Experimental Variables Contributing to Dissolution Variance. Pharm. Res. 2008, 25 (5), Liddell, M.; Deng, G.; Hauck, W. W. Dissolution testing variablility: effect of using vessels from different commercial sources. Am. Pharm. Rev. 2007, 10 (6), diss indd 15 5/27/2011 1:54:44 PM
Enhanced Mechanical Calibration of Dissolution Test Equipment
dx.doi.org/10.14227/dt180211p25 Enhanced Mechanical Calibration of Dissolution Test Equipment Alger Salt 1, * and John Glennon 2 1 GlaxoSmithKline, Product Development Laboratory Automation and Platforms,
More informationSuccessfully Implementing Mechanical Qualification for Dissolution Apparatus 1 and 2
Successfully Implementing Mechanical Qualification for Dissolution Apparatus 1 and 2 Ken Boda and Bryan Crist Agilent Technologies Dissolution Systems Agenda Mechanical Qualification Standards When You
More informationMethod Development and Validation for Online UV-Dissolution Methods Using Fiber-Optic Technology
Technical Overview Method Development and Validation for Online UV-Dissolution Methods Using Fiber-Optic Technology Introduction Online fiber-optic and multicell UV-dissolution systems have become increasingly
More informationAGILENT TECHNOLOGIES PRACTICAL SOLUTIONS NEWSLETTER
AGILENT TECHNOLOGIES PRACTICAL SOLUTIONS NEWSLETTER Volume 12, Issue 2 In This Issue: Enhanced Mechanical Qualification 1 Dissolution Qualification Timeline / Schedule 3 MQ Survey 4 MQ Guidance Summary
More informationA Simple and Economical Approach/Concept to Evaluate Quality of Pharmaceutical Products Based on an Improved Dissolution Testing Methodology
The Open Drug Delivery Journal, 2008, 2, 33-37 33 Open Access A Simple and Economical Approach/Concept to Evaluate Quality of Pharmaceutical Products Based on an Improved Dissolution Testing Methodology
More informationFor simple and accurate mechanical calibration.
For simple and accurate mechanical calibration. Regulatory Specifications and Recommendations Changes since 2007 in regulatory specifications now also allow enhanced mechanical calibration of dissolution
More informationAGILENT VACUUM-FORMED (VF) MOLDED DISSOLUTION VESSELS
AGILENT TECHNOLOGIES PRACTICAL SOLUTIONS NEWSLETTER VOLUME 15 ISSUE 3 PAGE 1 Agilent Vacuum-Formed (VF) Molded Dissolution Vessels PAGE 5 Learn. Solve. Discuss. PAGE 6 Gelatin Cross-linking and Dissolution
More informationPerformance Testing of Novel Dosage Forms
RQA Ireland Regional Forum - Athlone, May 2016 Quality Considerations Pharma and Biopharma Performance Testing of Novel Dosage Forms Terry Way BPharm MAPS Dissolution Science Consultant Glasside Technologies
More informationTHE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION
THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION Pharmacopeial Forum Vol. 31(5)(Sept.-Oct. 2005) By : Mr. Seubpong Kumpusiri Mrs. Patima Maneesatid 26 May 2006 THE DISSOLUTION PROCEDURE: DEVELOPMENT
More informationAGILENT TECHNOLOGIES PRACTICAL SOLUTIONS NEWSLETTER
AGILENT TECHNOLOGIES PRACTICAL SOLUTIONS NEWSLETTER VOLUME 16 ISSUE 4 PAGE 1 The 280-DS Mechanical Qualification System Not Just an Agilent Thing PAGE 3 You Asked, We Listened: New Inline Filtration for
More informationMASTER PLANNING FOR VALIDATION
MASTER PLANNING FOR VALIDATION By: Gamal Amer, Ph.D. Principal, Premier Compliance Services, Inc. 1 Process Validation: General Principles and Practices Guidance to industry issued by the FDA in January
More informationRecent FDA Guidance For Industry; BCS Class 1 and 3 August 2015
Recent FDA Guidance For Industry; BCS Class 1 and 3 August 2015 Bryan Crist Scientific Affairs Manager, Agilent Technologies, Dissolution Systems Dissolution Exchange WebEx Bryan.crist@agilent.com August,
More informationMarch Harmonization of Standards for Better Regulatory Compliance
March 2010 Harmonization of Standards for Better Regulatory Compliance Contents Abstract 2 High Level Interpretation of USP 3 High Level Interpretation of ASTM E2500 07 4 Aligning ASTM E2500 concepts
More informationDISSOLUTION TESTING OF GELS, TOPICAL CREAMS & OINTMENTS
AGILENT TECHNOLOGIES PRACTICAL SOLUTIONS NEWSLETTER VOLUME 15 ISSUE 4 PAGE 1 Dissolution Testing of Gels, Topical Creams & Ointments PAGE 4 Dispelling a Myth: 6- versus 12-Position Dissolution Units PAGE
More informationDeveloping and Validating Dissolution Procedures for Improved Product Quality
W H I T E P A P E R Developing and Validating Dissolution Procedures for Improved Product Quality By Michael Swartz, Ph. D., Director of Research and Development, and Mark Emanuele, Chemist Abstract In
More informationTransferring Dissolution Methods. Kenneth Boda Applications Engineer
Transferring Dissolution Methods Kenneth Boda Applications Engineer Agenda Prerequisites of a Method Transfer Transferring a Method to Automation Transferring a Method to Another Lab Determining Appropriate
More informationEffect of Various Operational Parameters on Drug Release from a 1% Hydrocortisone Semisolid Dosage Form Using the Vertical Diffusion Cell Apparatus
dx.doi.org/10.14227/dt190312p6 Effect of Various Operational Parameters on Drug Release from a 1% Hydrocortisone Semisolid Dosage Form Using the Vertical Diffusion Cell Apparatus e-mail: ess@usp.org Loice
More informationAT 70smart Fully Automated Dissolution System
AT 70smart Fully Automated Dissolution System Fully automated from media preparation to data reporting Batch up to 40 lots of Apparatus 1 or 2 methods including the use of sinkers Powerful DoE screening
More informationINTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article INTRODUCTION AND GENERAL OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION: A REVIEW Pandita Rachna* 1, Rana A C
More informationDissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances
Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances Guidance for Industry U.S. Department of Health and Human
More informationDissolution Apparatus Types
Dissolution Apparatus Types Thank you for reading. As you may know, people have look numerous times for their favorite books like this, but end up in infectious downloads. Rather than enjoying a good book
More information1 Analytical Validation within the Pharmaceutical Lifecycle
1 1 Analytical Validation within the Pharmaceutical Lifecycle Phil Nethercote and Joachim Ermer 1.1 Development of Process and Analytical Validation Concepts The concept of validation in the pharmaceutical
More informationTroubleshooting Differences Between Labs. Ken Boda Dissolution Applications Engineer
Troubleshooting Differences Between Labs Ken Boda Dissolution Applications Engineer Agenda Dissolution Run Failure Investigation Differences in data between sites Potential causes of site to site differences
More informationReflection paper on the dissolution specification for generic solid oral immediate release products with systemic action
10 August 2017 EMA/CHMP/CVMP/QWP/336031/2017 Committee for Medicinal Products for Human use (CHMP) Committee for Medicinal Products for Veterinary use (CVMP) Quality Working Party (QWP) Reflection paper
More information29-Apr Outline. Automation in dissolution testing. Mumbai , May 4 Samir Haddouchi
Automation in dissolution testing Mumbai - 2013, May 4 Samir Haddouchi samir.haddouchi@sps-pharma.com 1 Outline - Introduction about automation - Automation for dissolution testing - Validation of automated
More informationCHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE
CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE Paul Stott, PhD Head of US Product Development AstraZeneca ICH Quality Guidelines Workshop BioKorea 2007 Sept 13-14
More informationQUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS
QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS Guideline Title Quality of Prolonged Release Oral Solid Dosage Forms Legislative basis Directive 75/318/EEC as amended Date of first adoption October
More informationLifecycle Management Concepts to analytical Procedures: A compendial perspective. Horacio Pappa, Ph.D. Director - General Chapters U.S.
Lifecycle Management Concepts to analytical Procedures: A compendial perspective Horacio Pappa, Ph.D. Director - General Chapters U.S. Pharmacopeia USP Definitions Validation of Compendial Procedures
More informationRegulatory Assessment
Implementation of ICH Q8, Q9, Q10 Regulatory Assessment International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Presentation Overview Goal
More informationInternational Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:
Review Article CODEN: IJRPJK ISSN: 2319 9563 International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: www.ijrpns.com REVIEW ARTICLE ON INPROCESS PROBLEMS AND EVALUATION TESTS
More informationMISSION STATEMENT ABOUT US DISTEK S MISSION DISTEK S VISION AND VALUES
ABOUT US MISSION STATEMENT DISTEK S MISSION Distek, Inc. is a leading manufacturer of pharmaceutical laboratory instruments, specializing in dissolution testing products, as well as an experienced provider
More informationGuidelines for Process Validation of Pharmaceutical Dosage Forms
Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical
More informationThe AAPS Workshop on Special Dosage Forms
dx.doi.org/10.14227/dt170410p47 Workshop Summary: AAPS Workshop on Special Dosage Forms What s New with In Vitro Drug Release? e-mail: vagray@rcn.com Vivian Gray Dissolution Technologies, Hockessin, DE
More informationCE 7smart Flow-Through Dissolution System
CE 7smart Flow-Through Dissolution System In-vitro drug release testing in compliance with USP apparatus 4, EP, and JP Configurations for various methods and analytical requirements Specific flow-through
More informationGUIDANCE NOTES ON ANALYTICAL METHOD VALIDATION
ON ANALYTICAL METHOD VALIDATION HSA September 2004 Reproduction prohibited for commercial purposes. Reproduction for internal use is authorised, provided the source is acknowledged. MQA Dir: DISK1\GUIDE-MQA-012A-004.doc
More informationProposed New USP General Chapter: The Analytical Procedure Lifecycle 1220
Page 1 of 9 STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts Proposed New USP General Chapter: The Analytical Procedure
More informationAssessment of drug dissolution from solid oral
dx.doi.org/10.14227/dt110404p13 A New Crescent-shaped Spindle for Drug Dissolution Testing But Why a New Spindle? Saeed A. Qureshi, Ph.D. Senior Research Scientist Banting Research Centre (A/L 2202C1)
More informationUnderstanding the Characteristics and Establishing Acceptance Criteria for Analytical Methods Validation
Understanding the Characteristics and Establishing Acceptance Criteria for Analytical Methods Validation Ying Verdi IVT LAB WEEK EUROPE June 2017 Partners in Health Since 1919 Regulatory View of Method
More informationQbD and the New Process Validation Guidance
Page 1 of 6 Published on Pharmaceutical Processing (http://www.pharmpro.com) Home > QbD and the New Process Validation Guidance QbD and the New Process Validation Guidance Bikash Chatterjee and Wai Wong,
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL DISSOLUTION This guideline is intended to provide recommendations to applicants wishing to submit applications for the registration of medicines. It represents the Medicines Control
More informationQbD implementation in Generic Industry: Overview and Case-Study
QbD implementation in Generic Industry: Overview and Case-Study Inna Ben-Anat, QbD Strategy Leader, Teva Pharmaceuticals IFPAC JAN 2013 R&D Three Core Components of QbD and Generic Industry: How Do They
More informationfor IND and RDRC Regulated PET Compounding
Overview of USP Chapter for IND and RDRC Regulated PET Compounding Distributed Manufacturing of PET Radiopharmaceuticals for Multi-Center Clinical Trials SNM, Annual Meeting Toronto, Ontario, Canada
More informationá1058ñ ANALYTICAL INSTRUMENT QUALIFICATION
USP 41 General Information / á1058ñ 1 á1058ñ ANALYTICAL INSTRUMENT QUALIFICATION INTRODUCTION A large variety of analytical instruments, ranging from a simple apparatus to complex computerized systems,
More informationUSP <1223> Revision and the Alternative Microbiological Methods Workshop Tony Cundell, Ph. D. Consulting Microbiologist, Scarsdale, New York, USA
USP Revision and the Alternative Microbiological Methods Workshop Tony Cundell, Ph. D. Consulting Microbiologist, Scarsdale, New York, USA September, 2015 biomerieux Meeting 1 Presentation Outline
More informationBCS, Biowaivers and Dissolution Test Methodologies
BCS, Biowaivers and Dissolution Test Methodologies Vinod P. Shah, Ph.D., FAAPS, FFIP Pharmaceutical Consultant, (Formerly with US FDA) North Potomac, MD., USA Disso Europe 2016 Romania Advances and Applications
More informationLatino America Consultores Innovation & Technology to make your Business Compliant
Latino America Consultores Innovation & Technology to make your Business Compliant Annex 15 & EMA Process Validation Guide Line 1 Changes in Requirements The Pharmaceutical Industry has adapted its business
More informationAgilent 8453 Spectrophotometer and UV-visible ChemStation for Dissolution Testing. Solution Bundles for automated Dissolution Testing
Agilent 8453 Spectrophotometer and UV-visible ChemStation for Dissolution Testing Solution Bundles for automated Dissolution Testing General considerations UV benefits Simple, rugged and reliable equipment
More informationReal-Time Prediction of Polymer-Coated Multiparticulate Dissolution using Process Analytical Technology
Real-Time Prediction of Polymer-Coated Multiparticulate Dissolution using Process Analytical Technology Authors: Piyush Patel A, Edward Godek B, Chris O Callaghan C, Dr. Ian Jones D A Colorcon, PA, USA
More informationCurrent Features of USFDA and EMA Process Validation Guidance
Human Journals Review Article April 2016 Vol.:6, Issue:1 All rights are reserved by Patwekar S.L et al. Current Features of USFDA and EMA Process Validation Guidance Keywords: Pharmaceutical validation,
More informationCommon Issues in Qualification and Validation of Analytical Procedures
Common Issues in Qualification and Validation of Analytical Procedures Alexey Khrenov, PhD OTAT/CBER/FDA CMC Strategy Forum January 29, 2018 - Washington, DC Disclaimer These comments are an informal communication
More informationManaging Quality in Pharmaceutical Industry Using Six Sigma. Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA
Managing Quality in Pharmaceutical Industry Using Six Sigma Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA Outlines Pharmaceutical Manufacturing Process and Drug Product Quality. Process Excellence Approach
More informationDrug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel
Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel On February 13th, 2006, the FOOD AND DRUG ADMINISTRATION (FDA) implemented a revision to the Compliance Program Guidance Manual for active
More informationTEMPLATE FOR AN EXAMPLE METHODS VALIDATION STANDARD OPERATING PROCEDURE (SOP)
APPENDIX II TEMPLATE FOR AN EXAMPLE METHODS VALIDATION STANDARD OPERATING PROCEDURE (SOP) SOP EXAMPLE TEMPLATE 1. PURPOSE 1.1 This procedure is intended to provide general guidelines for the validation
More informationStage 3 - Process Validation: Measuring what matters
Stage 3 - Process Validation: Measuring what matters Trevor Schoerie - PharmOut A quote. The company that fails is the company that comes to us and says Just tell us what to do and we will do it. The company
More informationAgilent Resources for Workflow Compliance MEASURING ELEMENTAL IMPURITIES IN PHARMACEUTICAL MATERIALS
Agilent Resources for Workflow Compliance MEASURING ELEMENTAL IMPURITIES IN PHARMACEUTICAL MATERIALS AGILENT SOLUTIONS USP / & ICH Q3D Implementing Elemental Impurities Tests in the Pharmaceutical
More informationApplication of USP Apparatus 7 to In Vitro Drug Release in Scopolamine Transdermal Systems
dx.doi.org/10.14227/dt140207p25 Application of USP Apparatus 7 to In Vitro Drug Release in Scopolamine Transdermal Systems Marilyn X. Zhou 1, Duane Shoudt, Genaro Calderon, and Min Feng Analytical Research
More informationPHARMA TEST Dissolution Mechanical Calibration
Pharma Test Dissolution Automatisation PHARMA TEST Dissolution Mechanical Calibration Dissolution Testers, Pumps and Spectrophotometers 24-Nov-11 Requirements EP, USP, FDA, ASTM Dissolution 2 24-Nov-11
More informationAnalytical Procedures and Methods Validation for Drugs and Biologics
Final Guidance for Industry Analytical Procedures and Methods Validation for Drugs and Biologics Analytical procedures and Method Validation June 21, 2016 Lokesh Bhattacharyya Chief, LACBRP/DBSQC OCBQ/CBER/FDA
More informationIJPRD, 2013; Vol 5(02): April-2013 ( ) International Standard Serial Number
IJPRD, 2013; Vol 5(02): April-2013 (106 112) International Standard Serial Number 0974 9446 --------------------------------------------------------------------------------------------------------------------------------------------------
More informationApplication of PAT for Tablet Analysis. Case examples from Novartis Lorenz Liesum, Lead PAT Hamburg, 19 th of April 2013
Application of PAT for Tablet Analysis Case examples from Novartis Lorenz Liesum, Lead PAT Hamburg, 19 th of April 2013 Agenda PAT@Novartis Organization Business Drivers and Cases NIR Spectroscopy for
More informationNIRS, PAT, RTR testing EU experience and regulatory perspective
NIRS, PAT, RTR testing EU experience and regulatory perspective Heidelberg, Germany October 2013 European Compliance Academy (ECA) Overview of the presentation General considerations Cases submitted in
More informationInternational Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW
International Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW SUKHDEV SINGH *1 AND JASBIR SINGH 2 1 Rayat Institute
More informationIndustry Perspective on Manufacturing in Early Development
Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical
More informationChristine Oechslein. GMP Focus. Managing Process Validation. A Drugmaker s Guide. PDF Download. Excerpt from the GMP MANUAL
Christine Oechslein GMP Focus Managing Process Validation A Drugmaker s Guide PDF Download Excerpt from the GMP MANUAL Bibliographic Data of the Deutsche Nationalbibliothek: http://dnb.ddb.de ISBN: 978-3-95807-056-1
More informationValidation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals.
Validation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals. 1 Analytical Method Validation: 1..1 Philosophy: Method validation is
More information2018 by Agilent Technologies Agilent CrossLab Compliance Services
EQP Name: Service Type: OQ Company Name: Customer Name/Title: EQP Filename: Standard_EQP Diss.01.11.eqp EQP Release Date: January 2017 Print Date: Page 1 / 17 Table of Contents Section Page Page 2 / 17
More informationValidation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH)
Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH) *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY!
More informationQuality by Design Considerations for Analytical Procedures and Process Control
Quality by Design Considerations for Analytical Procedures and Process Control Moheb M. Nasr, Ph.D. ONDQA/CDER/FDA IFPAC 2009 Baltimore, MD January 26, 2009 1 Outline Background on FDA Initiatives and
More informationICH Q8/Q8(R)
Pharmaceutical Quality for the 21 st Century Temple University May 06, 2008 Joseph Famulare, Deputy Director FDA CDER Office of Compliance CDER Office of Compliance and the Critical Path Initiative Since
More informationCRITICAL ASPECT ANALYTICAL TEST REVIEW
CRITICAL ASPECT ANALYTICAL TEST REVIEW Jakarta 14 December 2017 Speaker: HERU PURNOMO, ST QC WORK FLOW Start Sample Received (In-Process & Finished Good) Testing Review Lab Result Yes No Non Conformance
More informationThese commentaries were received in response to a
dx.doi.org/10.14227/dt140207p6 These commentaries were received in response to a general invitation in the February 2007 issue to encourage dissolution experts and specialists to share their opinions on
More informationGMP Challenges to Global Pharma Companies
GMP Challenges to Global Pharma Companies Muralidhara B. Gavini, Ph.D. Senior Assistant Country Director India Mumbai Office, Office of International Programs Office of the Commissioner Food & Drug Administration
More informationQbD Concepts Applied to Qualification and Transfer of Analytical Methods
QbD Concepts Applied to Qualification and Transfer of Analytical Methods CMC Strategy Forum Latin America - 2014 Patrick Swann Senior Director Technical Development QbD = Quality by Design QbD - A systematic
More information22 January Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852
22 January 2009 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 SUBMISSION OF COMMENTS, DOCKET NO. FDA-2008-D-0559 Dear Sir or Madam:
More informationThe procurement, qualification and calibration of lab instruments: An Overview
The procurement, qualification and calibration of lab instruments: An Overview The reliability of analytical data generated from chemical and physical analyses is critically dependent on three factors:
More informationDissolution Market. Vinod Mehta
Dissolution Market Vinod Mehta Objective Dissolution - What is it? Market and Product Situation Carl Zeiss Offering System Packages Competition What is Dissolution Solid dosage form assays in the pharmaceutical
More informationQ8 Pharmaceutical Development
Q8 Pharmaceutical Development For questions regarding this draft document contact (CDER) Ajaz Hussain at 301-594-2847 or (CBER) Christopher Joneckis at 301-435-5681. This draft guidance, when finalized,
More informationUS FDAs Perspective on Product Quality and Bioequivalence
US FDAs Perspective on Product Quality and Bioequivalence Vinod P. Shah, Ph. D. Pharmaceutical Consultant (Formerly with US FDA) Scientific Principles in Dissolution Methodology and Drug Testing Society
More informationProcess development and basic GMP
Process development and basic GMP Aulton Chapter 45, handouts Specification, stability, inprocess controls and validation Product development Process development Critical Product Qualities issues Critical
More informationProposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding <823>
Proposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding Ravi Ravichandran, Ph.D. Steve Zigler, Ph.D. February 21, 2011 Agenda Rationale for the
More informationModern Validation Technology Boot Camp
2018 Modern Validation Technology Boot Camp Modern Process validation Risk based Modern cleaning Validation Facility and equipment qualification? Risk analysis Advanced Topics Protocols and SOPs 6700 TransCanada,
More informationConsultation response: Dissolution testing in BP finished products monographs for solid oral dosage forms
Consultation response: Dissolution testing in BP finished products monographs for solid oral dosage forms Background Oral dosage forms are the most convenient and widely used drug presentations. For solid
More informationAccording to USP <1058>
Analytical l Instrument t Qualification According to USP Scope, Approach, Requirements Dr. Ludwig Huber Chief Advisor, Global FDA Compliance ludwig_huber@labcompliance.com Overview FDA and International
More informationConnection Between Quality, Safety, and Efficacy
PQRI-FDA Workshop on Process Drift Bethesda, Maryland Connection Between Quality, Safety, and Efficacy Roger L. Williams, M.D. United States Pharmacopeial Convention December 1 3, 2010 Topics Overview
More informationWho we are? Dissolution testing of modified release forms. Dissolution testing of immediate/ modified release forms
Dissolution testing of modified release forms Mumbai - 2013, May 3 Samir Haddouchi samir.haddouchi@sps-pharma.com 1 Dissolution testing of immediate/ modified release forms Mumbai - 2013, May 3 Samir Haddouchi
More informationReference Standard Characterization. Steve Lane. General Manager, NSF Reference Standards.
Reference Standard Characterization Steve Lane General Manager, NSF Reference Standards www.nsf-rs.org Regulatory Bodies will require that an Excipient: Be safe in the amount or dose used Meet applicable
More informationRegulatory Requirements of Dissolution for Generic Drug Products
Regulatory Requirements of Dissolution for Generic Drug Products Om Anand, Ph.D. Division of Biopharmaceutics, Office of New Drug Products, Office of Pharmaceutical Quality - CDER, US-FDA International
More informationWARNING LETTER AUG 3, 2016
Ropack, Inc. 8/3/16 Department of Health and Human Services Public Health Service Food and Drug Administration 10903 New Hampshire Avenue White Oak Building 66 Silver Spring, MD 20993 WARNING LETTER AUG
More informationDissolution and clinically relevant specifications: linking clinical performance to dissolution
Dissolution and clinically relevant specifications: linking clinical performance to dissolution Talia Flanagan, Dave Holt, Paul Dickinson, Paul Stott. FDA/PQRI Conference on Evolving Product Quality 16-17
More information10 November, 2016 Moderated by Bryan Crist Agilent Technologies
10 November, 2016 Moderated by Bryan Crist Agilent Technologies 1 Welcome to the DDG Online Meeting DDG Online Meeting number 24, the fourth and final in 2016; our 6 th year of consecutive meetings Worldwide
More informationFDA Process Validation
Page 1 of 5 Published on Controlled Environments Magazine (http://www.cemag.us) Home > FDA Process Validation FDA Process Validation Wai Wong Working with the New 2011 Guidelines. In January 2011, the
More informationPerspectives on Method Validation: Importance of Adequate Method Validation
Perspectives on Method Validation: Importance of Adequate Method Validation Heather Bridwell, Vikas Dhingra, Daniel Peckman, Jennifer Roark and Thomas Lehman The appropriate validation of analytical methods
More informationAvailable online at ScienceDirect. Procedia Engineering 132 (2015 )
Available online at www.sciencedirect.com ScienceDirect Procedia Engineering 132 (2015 ) 811 815 The Manufacturing Engineering Society International Conference, MESIC 2015 Metrological Regulations for
More informationGuidance for Industry
Guidance for Industry Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationPAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland
PAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec 2004 Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland cca@iol.ie 1 FDA Context 1) FDA 5-Part Strategic Plan Protect &
More informationApplications of USP Apparatus 3: Reciprocating Cylinder
Applications of USP Apparatus 3: Reciprocating Cylinder Ken Boda Bryan Crist Agilent Technologies Current Trends in Pharmaceutical Dissolution Testing Workshop Pittcon 2015 Tuesday, March 10 Development
More informationSCIENCE AND RISK BASED APPROACH TO THE PROCESS VALIDATION LINK FROM QUALITY BY DESIGN TO PROCESS VALIDATION.
IJPSR (2016), Vol. 7, Issue 3 (Review Article) Received on 09 September, 2015; received in revised form, 15 December, 2015; accepted, 05 February, 2016; published 01 March, 2016 SCIENCE AND RISK BASED
More informationManual 055 Commercial Stability Testing For Formulated Products. This procedure applies to all drug products. The procedure covers:
1 Purpose Manual 055 Commercial Stability Testing For Formulated Products The intent of this procedure is to provide to manufacturing and primary packaging sites the principles of a stability program.
More informationLifecycle Product Quality Risk Management
Lifecycle Product Quality Risk Management Richard L. Friedman, M.S. Associate Director Office of Manufacturing and Product Quality Office of Compliance IFPAC Annual Meeting (Arlington, VA) January, 21-24,
More informationInspection. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory
More information